The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Private equity OpCapita buys owner of Rossopomodoro pizza chain

Fri, 09th Mar 2018 15:51

MILAN, March 9 (Reuters) - European private equity firmOpCapita said on Friday it had reached a deal to buy themajority of Sebeto, an Italian restaurant group whose assetsinclude pizza chain Rossopomodoro.

* The deal values Sebeto at more than 80 million euros ($99million), including debt, two sources with knowledge of thematter said. OpCapita did not say how much it paid for Sebeto.

* OpCapita acquired the restaurant operator fromLondon-basedprivate equity firm Change Capital.

* The buyer said it saw significant potential to grow theRossopomodoro brand in Italy and abroad, exploiting itsNeapolitan heritage.

* The fund has picked new managers to strengthen the Sebetoteam,including former CEO of Benetton group Marco Airoldi and COO oftravel caterer Autogrill Roberto Colombo.

* Change Capital was advised on the deal by Rothschild withLegance as legal adviser, while Lazard and legal firm Chiomentiadvised OpCapita on the deal.

* Studio Legale Ambrosino-Pecora advised Sebeto founders andothershareholders.($1 = 0.8117 euros)(Reporting by Francesca Landini; Editing by Susan Fenton)

Related Shares

More News
5 Jun 2024 16:32

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

5 Jun 2024 10:08

Angle unveils plans to raise more than £10m

(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.

16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.